# Ouster, Inc.: financial statements, quarterly

OUST · Nasdaq · CIK 1816581 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oust.md) · [Financials](/companies/oust/financials.md) · [Filings](/companies/oust/filings.md) · [Insiders](/companies/oust/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/oust/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [22.2](/filings/0001628280-24-046736.md) | [24.4 d](/filings/0001628280-25-014318.md) | [25.9](/filings/0001628280-25-024281.md) | [27.0](/filings/0001628280-25-039599.md) | [28.1](/filings/0001628280-25-049640.md) | [30.1 d](/filings/0001628280-26-013313.md) | [32.6](/filings/0001628280-26-030722.md) | [35.0](/filings/0001628280-26-054467.md) | [39.5](/filings/0001628280-25-049640.md) | [62.2 d](/filings/0001628280-26-013313.md) | [48.6](/filings/0001628280-26-030722.md) | [54.6](/filings/0001628280-26-054467.md) |
| Cost of revenue | $m | [19.1](/filings/0001628280-24-046736.md) | [19.0 d](/filings/0001628280-25-014318.md) | [18.5](/filings/0001628280-25-024281.md) | [17.9](/filings/0001628280-25-039599.md) | [17.3](/filings/0001628280-25-049640.md) | [16.9 d](/filings/0001628280-26-013313.md) | [19.1](/filings/0001628280-26-030722.md) | [19.2](/filings/0001628280-26-054467.md) | [22.9](/filings/0001628280-25-049640.md) | [24.7 d](/filings/0001628280-26-013313.md) | [27.7](/filings/0001628280-26-030722.md) | [27.9](/filings/0001628280-26-054467.md) |
| Gross profit | $m | [3.1](/filings/0001628280-24-046736.md) | [5.4 d](/filings/0001628280-25-014318.md) | [7.4](/filings/0001628280-25-024281.md) | [9.1](/filings/0001628280-25-039599.md) | [10.8](/filings/0001628280-25-049640.md) | [13.2 d](/filings/0001628280-26-013313.md) | [13.5](/filings/0001628280-26-030722.md) | [15.8](/filings/0001628280-26-054467.md) | [16.7](/filings/0001628280-25-049640.md) | [37.5 d](/filings/0001628280-26-013313.md) | [20.8](/filings/0001628280-26-030722.md) | [26.7](/filings/0001628280-26-054467.md) |
| Research and development | $m | [16.7](/filings/0001628280-24-046736.md) | [15.6 d](/filings/0001628280-25-014318.md) | [13.8](/filings/0001628280-25-024281.md) | [14.4](/filings/0001628280-25-039599.md) | [15.1](/filings/0001628280-25-049640.md) | [14.7 d](/filings/0001628280-26-013313.md) | [15.0](/filings/0001628280-26-030722.md) | [17.1](/filings/0001628280-26-054467.md) | [17.8](/filings/0001628280-25-049640.md) | [15.3 d](/filings/0001628280-26-013313.md) | [16.1](/filings/0001628280-26-030722.md) | [19.3](/filings/0001628280-26-054467.md) |
| Operating income | $m | [(35.7)](/filings/0001628280-24-046736.md) | [(37.3) d](/filings/0001628280-25-014318.md) | [(25.8)](/filings/0001628280-25-024281.md) | [(25.3)](/filings/0001628280-25-039599.md) | [(27.5)](/filings/0001628280-25-049640.md) | [(25.6) d](/filings/0001628280-26-013313.md) | [(23.8)](/filings/0001628280-26-030722.md) | [(26.8)](/filings/0001628280-26-054467.md) | [(24.3)](/filings/0001628280-25-049640.md) | [0.9 d](/filings/0001628280-26-013313.md) | [(19.2)](/filings/0001628280-26-030722.md) | [(20.0)](/filings/0001628280-26-054467.md) |
| Interest expense | $m | [1.8](/filings/0001628280-23-038609.md) | [4.1 d](/filings/0001628280-24-013619.md) | [0.7](/filings/0001628280-24-022948.md) | [0.7](/filings/0001628280-25-039599.md) | [0.3](/filings/0001628280-25-049640.md) | [0.0 d](/filings/0001628280-26-013313.md) | [0.0](/filings/0001628280-25-024281.md) | [0.0](/filings/0001628280-25-039599.md) | [0.0](/filings/0001628280-25-049640.md) | [0.0 d](/filings/0001628280-26-013313.md) | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001628280-24-046736.md) | [0.2 d](/filings/0001628280-25-014318.md) | [0.1](/filings/0001628280-25-024281.md) | [0.1](/filings/0001628280-25-039599.md) | [(0.0)](/filings/0001628280-25-049640.md) | [0.3 d](/filings/0001628280-26-013313.md) | [0.2](/filings/0001628280-26-030722.md) | [(3.6)](/filings/0001628280-26-054467.md) | [0.1](/filings/0001628280-25-049640.md) | [0.4 d](/filings/0001628280-26-013313.md) | [0.6](/filings/0001628280-26-030722.md) | [0.1](/filings/0001628280-26-054467.md) |
| Net income | $m | [(35.1)](/filings/0001628280-24-046736.md) | [(39.0) d](/filings/0001628280-25-014318.md) | [(23.8)](/filings/0001628280-25-049640.md) | [(23.9)](/filings/0001628280-25-049640.md) | [(25.6)](/filings/0001628280-25-049640.md) | [(23.7) d](/filings/0001628280-26-013313.md) | [(22.0)](/filings/0001628280-26-054467.md) | [(20.6)](/filings/0001628280-26-054467.md) | [(21.7)](/filings/0001628280-25-049640.md) | [4.0 d](/filings/0001628280-26-013313.md) | [(17.5)](/filings/0001628280-26-054467.md) | [(18.1)](/filings/0001628280-26-054467.md) |
| Diluted EPS | $ per share | [(0.89)](/filings/0001628280-24-046736.md) | not reported | [(0.55)](/filings/0001628280-25-024281.md) | [(0.53)](/filings/0001628280-25-039599.md) | [(0.54)](/filings/0001628280-25-049640.md) | not reported | [(0.42)](/filings/0001628280-26-030722.md) | [(0.38)](/filings/0001628280-26-054467.md) | [(0.37)](/filings/0001628280-25-049640.md) | not reported | [(0.28)](/filings/0001628280-26-030722.md) | [(0.27)](/filings/0001628280-26-054467.md) |
| Basic EPS | $ per share | [(0.89)](/filings/0001628280-24-046736.md) | not reported | [(0.55)](/filings/0001628280-25-024281.md) | [(0.53)](/filings/0001628280-25-039599.md) | [(0.54)](/filings/0001628280-25-049640.md) | not reported | [(0.42)](/filings/0001628280-26-030722.md) | [(0.38)](/filings/0001628280-26-054467.md) | [(0.37)](/filings/0001628280-25-049640.md) | not reported | [(0.28)](/filings/0001628280-26-030722.md) | [(0.27)](/filings/0001628280-26-054467.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [75.6](/filings/0001628280-24-046736.md) | [51.0](/filings/0001628280-25-014318.md) | [48.3](/filings/0001628280-25-024281.md) | [52.7](/filings/0001628280-25-039599.md) | [44.4](/filings/0001628280-25-049640.md) | [45.5](/filings/0001628280-26-013313.md) | [54.0](/filings/0001628280-26-030722.md) | [76.1](/filings/0001628280-26-054467.md) | [87.1](/filings/0001628280-25-049640.md) | [67.4](/filings/0001628280-26-054467.md) | [78.7](/filings/0001628280-26-030722.md) | [91.8](/filings/0001628280-26-054467.md) |
| Current assets | $m | [253](/filings/0001628280-23-038609.md) | [263](/filings/0001628280-25-014318.md) | [256](/filings/0001628280-24-022948.md) | [252](/filings/0001628280-24-036996.md) | [200](/filings/0001628280-24-046736.md) | [220](/filings/0001628280-26-013313.md) | [219](/filings/0001628280-25-024281.md) | [273](/filings/0001628280-25-039599.md) | [305](/filings/0001628280-25-049640.md) | [279](/filings/0001628280-26-054467.md) | [251](/filings/0001628280-26-030722.md) | [346](/filings/0001628280-26-054467.md) |
| Total assets | $m | [322](/filings/0001628280-23-038609.md) | [331](/filings/0001628280-25-014318.md) | [318](/filings/0001628280-24-022948.md) | [310](/filings/0001628280-24-036996.md) | [255](/filings/0001628280-24-046736.md) | [276](/filings/0001628280-26-013313.md) | [269](/filings/0001628280-25-024281.md) | [322](/filings/0001628280-25-039599.md) | [354](/filings/0001628280-25-049640.md) | [350](/filings/0001628280-26-054467.md) | [382](/filings/0001628280-26-030722.md) | [475](/filings/0001628280-26-054467.md) |
| Current liabilities | $m | [61.6](/filings/0001628280-23-038609.md) | [81.7](/filings/0001628280-25-014318.md) | [83.1](/filings/0001628280-24-022948.md) | [74.1](/filings/0001628280-24-036996.md) | [64.1](/filings/0001628280-24-046736.md) | [78.4](/filings/0001628280-26-013313.md) | [85.0](/filings/0001628280-25-024281.md) | [86.1](/filings/0001628280-25-039599.md) | [93.8](/filings/0001628280-25-049640.md) | [71.0](/filings/0001628280-26-054467.md) | [84.3](/filings/0001628280-26-030722.md) | [83.0](/filings/0001628280-26-054467.md) |
| Total liabilities | $m | [128](/filings/0001628280-23-038609.md) | [151](/filings/0001628280-25-014318.md) | [150](/filings/0001628280-24-022948.md) | [139](/filings/0001628280-24-036996.md) | [83.5](/filings/0001628280-24-046736.md) | [95.2](/filings/0001628280-26-013313.md) | [101](/filings/0001628280-25-024281.md) | [101](/filings/0001628280-25-039599.md) | [106](/filings/0001628280-25-049640.md) | [87.8](/filings/0001628280-26-054467.md) | [106](/filings/0001628280-26-030722.md) | [104](/filings/0001628280-26-054467.md) |
| Long-term debt | $m | [40.4](/filings/0001628280-23-038609.md) | [44.0](/filings/0001628280-25-014318.md) | [44.0](/filings/0001628280-24-022948.md) | [44.0](/filings/0001628280-24-036996.md) | [0.0](/filings/0001628280-24-046736.md) | [0.0](/filings/0001628280-25-014318.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [194](/filings/0001628280-24-046736.md) | [180](/filings/0001628280-26-013313.md) | [167](/filings/0001628280-25-049640.md) | [171](/filings/0001628280-25-049640.md) | [172](/filings/0001628280-25-049640.md) | [181](/filings/0001628280-26-054467.md) | [168](/filings/0001628280-26-054467.md) | [221](/filings/0001628280-26-054467.md) | [247](/filings/0001628280-25-049640.md) | [262](/filings/0001628280-26-054467.md) | [276](/filings/0001628280-26-054467.md) | [371](/filings/0001628280-26-054467.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(27.2) d](/filings/0001628280-24-046736.md) | [(24.2) d](/filings/0001628280-25-014318.md) | [(5.7)](/filings/0001628280-25-024281.md) | [(21.6) d](/filings/0001628280-25-039599.md) | [(3.8) d](/filings/0001628280-25-049640.md) | [(2.6) d](/filings/0001628280-26-013313.md) | [(4.9)](/filings/0001628280-26-030722.md) | [(1.3) d](/filings/0001628280-26-054467.md) | [(18.3) d](/filings/0001628280-25-049640.md) | [(15.4) d](/filings/0001628280-26-013313.md) | [(7.3)](/filings/0001628280-26-030722.md) | [(12.8) d](/filings/0001628280-26-054467.md) |
| Capital expenditure | $m | [0.7 d](/filings/0001628280-24-046736.md) | [0.4 d](/filings/0001628280-25-014318.md) | [1.4](/filings/0001628280-25-024281.md) | [0.4 d](/filings/0001628280-25-039599.md) | [0.6 d](/filings/0001628280-25-049640.md) | [1.4 d](/filings/0001628280-26-013313.md) | [0.6](/filings/0001628280-26-030722.md) | [0.9 d](/filings/0001628280-26-054467.md) | [1.7 d](/filings/0001628280-25-049640.md) | [21.8 d](/filings/0001628280-26-013313.md) | [2.6](/filings/0001628280-26-030722.md) | [2.6 d](/filings/0001628280-26-054467.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-23-038609.md) | [0.0 d](/filings/0001628280-24-013619.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q4 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [18.1](/filings/0001628280-23-038609.md) | [29.4](/filings/0001628280-24-022948.md) | [38.4](/filings/0001628280-24-036996.md) | [39.2](/filings/0001628280-24-046736.md) | [43.5](/filings/0001628280-25-024281.md) | [44.7](/filings/0001628280-25-039599.md) | [47.7](/filings/0001628280-25-049640.md) | [52.5](/filings/0001628280-26-030722.md) | [54.5](/filings/0001628280-26-054467.md) | [58.0](/filings/0001628280-25-049640.md) | [61.8](/filings/0001628280-26-030722.md) | [66.0](/filings/0001628280-26-054467.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 72,112,333 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054467.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.